Overview

* Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations

* Net loss per share decreases 46% for fiscal Q2 compared to last year

* U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales

Outlook

* Company expects positive growth trajectory with increasing product adoption

Result Drivers

* U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales

* NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth

* REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $5.60 $4.26

Revenue mln mln (1

Analyst)

Q2 EPS -$0.32

Q2 Net -$500,00

Income 0

Q2 -$200,00

EBITDA 0

Q2 Gross $2.10

Profit mln

Q2 $2.50

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc ( SNOA ) is $14.80, about 74.5% above its November 3 closing price of $3.78

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)